InterCure Ltd. (NASDAQ:INCR – Get Free Report) was the recipient of a significant growth in short interest in February. As of February 27th, there was short interest totaling 20,573 shares, a growth of 320.4% from the February 12th total of 4,894 shares. Based on an average daily trading volume, of 84,411 shares, the days-to-cover ratio is presently 0.2 days. Currently, 0.0% of the company’s stock are sold short. Currently, 0.0% of the company’s stock are sold short. Based on an average daily trading volume, of 84,411 shares, the days-to-cover ratio is presently 0.2 days.
InterCure Stock Down 1.0%
Shares of NASDAQ INCR traded down $0.01 during mid-day trading on Wednesday, reaching $0.81. 26,080 shares of the company traded hands, compared to its average volume of 63,046. The company’s fifty day moving average is $0.91 and its two-hundred day moving average is $1.25. The company has a debt-to-equity ratio of 0.27, a quick ratio of 1.09 and a current ratio of 1.85. InterCure has a fifty-two week low of $0.68 and a fifty-two week high of $1.77.
Wall Street Analyst Weigh In
Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of InterCure in a research report on Monday, December 29th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company currently has a consensus rating of “Sell”.
InterCure Company Profile
InterCure Ltd is an Israel-based medical cannabis company publicly listed on the Nasdaq Capital Market under the ticker INCR. The company’s operations span the entire value chain of medical cannabis, from the development of proprietary seed strains and controlled cultivation in a GMP-compliant facility to laboratory testing, cannabinoid extraction and formulation. InterCure serves licensed pharmacies and clinics within Israel and adheres to the regulatory framework established by the Israeli Ministry of Health.
Founded in 2013, InterCure has built a vertically integrated platform that supports both patient care and research initiatives.
Further Reading
- Five stocks we like better than InterCure
- The gold chart Wall Street is terrified of…
- What a Former CIA Agent Knows About the Coming Collapse
- Elon Musk already made me a “wealthy man”
- Unlocked: Elon Musk’s Next Big IPO
- 1,500 Banks Just Handed the Fed Your Bank Account
Receive News & Ratings for InterCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InterCure and related companies with MarketBeat.com's FREE daily email newsletter.
